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Case Presentation
The patient is a 68-year-old female with hypertension, chronic
obstructive pulmonary disease, without medical follow-up for
several years, who initially presented with skin blisters and oral
lesions, which were biopsied by her dermatologist and found to
be bullous pemphigoid. She was treated with a course of oral
prednisone and had resolution of her skin and oral lesions. Three
months later, she presented with a swollen leg and was diagnosed
with a deep venous thrombosis, for which she was started on
coumadin and had an inferior vena cava filter placed. She then
had hemoptysis a few days later, after which the coumadin was
held. A chest computed tomography (CT) done at that time found
a right middle lobe consolidation consistent with aspiration
pneumonia and a cavitary lesion in the left upper lobe of her
lung, which was biopsied and found to be a necrotizing cavitary
lung lesion. After being ruled out for tuberculosis, she had an
outpatient positron emission tomography (PET) scan which was
positive for a 2.7cm left lower lobe cavitary lesion and a 9 cm
pelvic mass with hypermetabolic activity, as well as small liver
lesions. Concurrently, she complained of dysphagia and 30-lbs of
weight loss over the prior six months, so the decision was made
to undergo an outpatient esophagogastroduodenoscopy (EGD).
The EGD could not be completed secondary to a stricture in the
distal esophagus; however, pemphigus ulcers were seen in the
mouth and esophagus. Given the patient’s degree of malnourishment and dehydration, she was admitted to the outside
hospital. On admission, she was found to have leukocytosis
with a white blood cell count of 37,000/L, hypercalcemia with a
calcium of 13mg/dL, hypotension, and acute renal failure with
a creatinine of 4.4mg/dL. Her parathyroid hormone-related
protein (PTHrP) was 105 pmol/L (normal <1.3 pmol/L), while
her intact parathyroid hormone (PTH) was <3pg/mL (10-55
pg/ml). A serum protein electrophoresis with immunoelectrophoreis was positive for an IgG lambda paraprotein. On bone
marrow biopsy, there were 25% plasma cells consistent with
multiple myeloma, though this diagnosis was questioned after
transfer. For treatment of her hypercalcemia, she was given
intravenous fluids and calcitonin with minimal improvement,
but with resolution of her renal failure.
The esophageal biopsy showed squamous mucosa with necrotic
ulcer and chronic inflammation with fibrinous exudate. The
pelvic mass was also biopsied which was consistent with carcinosarcoma with massive necrosis. The pathology revealed myxoid
high-grade spindle cell sarcoma with pleomorphosis and extensive
mitosis and poorly differentiated adenocarcinoma with papillary
serous differentiation, as well as some smooth muscle differentiation. During her hospitalization, the skin blisters reappeared
and were biopsied. The biopsy was consistent with paraneo-

plastic pemphigus. She was treated with three days of intravenous
immunoglobulin (IVIg). She had an open jejunostomy tube
placed for nutrition. At this point, she was transferred to Thomas
Jefferson University for further management.
Initial vital signs after transfer were within normal limits aside
from mild tachycardia. On physical exam, she was lethargic, but
oriented to person and place. She had a normal physical exam
other than a II/VI systolic ejection murmur, decreased breath
sounds in her right lung base, and tenderness to palpation
in the suprapubic region. She had no lymphadenopathy. A
non-bleeding ulcer could be seen in her oral cavity, while her
skin showed healing blisters (pictured below) without weeping.
A pelvic exam was performed and a necrotic mass was found to
be protruding into the cervix. Laboratory studies upon transfer
included a white blood cell count of 32,800/L, hemoglobin 8.5
g/dL, platelet count 362/L, CA-125 1300 U/mL (normal 0-35 U/
mL), creatinine 0.7 mg/dL, and calcium 9.9 mg/dL.
Dermatology was consulted and thought that her presentation
was more consistent with paraneoplastic pemphigus given
the combination of oral and skin lesions, rather than the
previously diagnosed bullous pemphigoid. Hematology
reviewed the initial bone marrow biopsy and concluded that it
was more consistent with myoclonal gammopathy of unknown
significance. Gynecology/Oncology stated that her prognosis
was poor and that her best option was palliative radiation, as
she was not a surgical candidate secondary to metastatic disease.
Her hospital course was complicated by an additional episode
of hypercalcemia causing mental status changes, and she was
effectively treated with a dose of pamidronate. After palliative
radiation, the patient was transferred to hospice care.

Figure 1. Healing skin blisters on abdomen
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A pauci-inflammatory subepidermal split can be seen at the
lateral aspect of the punch biopsy. Our dermatopathologist
believes that the split is not artifact, and represents abnormalities
at the dermal-epidermal junction. This finding can also be seen
in epidermolysis bullosa acquisita, bullous pemphigoid, other
subepidermal bullous diseases, but taken in conjunction with the
clinical history, it is consistent with paraneoplastic pemphigus.

Discussion

Figure 2: Oral ulcers

Figure 3: Skin biopsy pathology – H & E Stain at 10x Magnification
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Paraneoplastic Pemphigus (PNP) is a rare, autoimmune
blistering skin disorder, which occurs in the setting of a systemic
neoplasm. The disease is characterized by polymorphous skin
lesions, with a predilection for mucosal surfaces, along with
evidence of IgG auto-antibodies against epidermal proteins.
Paraneoplastic pemphigus was first described in 1990 by Anhalt
et al.1, and since then there have been over 200 cases reported
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in the literature. Patients in all age groups have been affected by
the disorder, including children and adolescents.2
Clinically, the presentation may be heterogeneous; however,
mucosal lesions are inevitably present. Patients generally
develop severe, painful stomatitis, and may have ulcerations
and erosions of the oropharynx, larynx, esophagus, eyes, and
genitalia.3 Cutaneous manifestations of the disease may vary
in morphology. Skin lesions resembling erythema multiforme,
graft-versus-host disease, lichen planus, as well as pemphigus
and pemphigoid have been reported. 3 Cutaneous findings
generally appear after the onset of mucosal eruptions and may
erupt in waves. Additionally, bronchiolitis obliterans may be
a complication of PNP, often leading to respiratory failure
and death. 4,5 Bronchial inflammation and destruction with
subsequent fibrosis appears to be caused by deposition of IgG
autoantibodies on bronchial epithelial cell surfaces and basement
membranes.6 Onset of dyspnea and dry cough in patients with
paraneoplastic pemphigus should warrant prompt attention
and therapy in order to avoid rapidly progressive respiratory
complications.
PNP is associated with a variety of neoplasms. Lymphoproliferative
disorders predominate, with non-Hodgkin’s lymphoma, chronic
lymphocytic leukemia, Castelman’s tumor, and thymoma
being the most common. 7 Of note, PNP with monoclonal
gammopathy has been reported as well. 8 Non-hematologic
neoplasms associated with PNP are liposarcoma, leiomyosarcoma, adenocarcinoma of the breast, colon, pancreas and
other organs, basal cell carcinoma, and malignant melanoma.9
The histopathology in PNP varies according to the morphologic
characteristics of the cutaneous lesions. Horn & Anhalt10 studied
the histology of 16 biopsy specimens from six patients with PNP,
and determined that there are a number of major features characteristic of the disorder. Acantholysis, or the loss of intercellular
connections between epidermal cells, was commonly noted in the
suprabasal region. Dyskeratotic keratinocytes, or the abnormal
keratinization of skin cells characterized by eosinophilic,
shrunken keratinocytes, was commonly seen at all epidermal
levels. Suprabasal clefts or blisters reminiscent of those seen in
pemphigus vulgaris, basal vascularization, and inflammatory
cell exocytosis into the epidermis were other major features
noted.10 The authors determined that both acantholysis and
dyskeratotic keratinocytes at all levels of the epidermis indicate
the presence of PNP.
A number of autoantibodies have been isolated in patients
with PNP. Antibodies to the plakin family of proteins, which
are structural proteins in hemidesmosomal and desmosomal
plaques, have been reported. 11 Anti-envoplakin and
anti-periplakin have been noted to be the most specific autoantibodies.8 Anti-desmogelin-3 and anti-desmoglein-1 are also
commonly isolated proteins. Autoantibodies may be detected
using immunoprecipitation of antigen complexes, Western
blot, and ELISA.11 It is likely that the diversity of autoantibodies
accounts for the wide clinical spectrum of PNP.

Immunofluorescence, both direct and indirect, is an important
component of the diagnosis of PNP. On direct immunofluorescence, deposits of IgG and complement in the epithelium are
distributed both intercellularly and at the basement membrane
zone.10,11 Indirect immunofluorescence may be used to detect
antibodies in sera, utilizing monkey esophagus or rat bladder
epithelium12. Using rat bladder as a substrate is more specific
for PNP, as autoantibodies found in pemphigus vulgaris do not
bind to transitional epithelia. However, indirect immunofluorescence may be negative in as many as one fourth of patients,
and in this case, immunoprecipitation should be used to aid in
the diagnosis.13
There have been a number of hypotheses regarding the
pathogenesis of PNP. Xuejun and Bingxin 14 isolated
B-lymphocyte clones from a Castleman’s tumor, which
specifically reacted to epidermal proteins, indicating that the
associated tumors may produce auto-antibodies. Other authors
have postulated that paraneoplastic skin eruptions promote
exposure of self-antigens and subsequent development of
auto-antibodies.15 Epitope spreading may then occur, where
tissue damage exposes additional self-antigens, thereby
diversifying the auto-antibodies to recognize additional
proteins.16
Criteria for diagnosis were devised by Anhalt and colleagues
in their original article.1 Those criteria have been revised into
major and minor features. Major features include polymorphic
mucocutaneous eruption, concomitant internal neoplasia, and
characteristic serum immunoprecipitation findings. Minor
criteria include evidence of acantholysis on histology, direct
immunofluorescence staining of intercellular and basement
membrane staining, and indirect immunofluorescence staining
of rat bladder epithelium. Patients meeting all three major
criteria and at least two minor criteria should be considered to
have PNP.17
Treatment of PNP includes early detection and resection of the
associated tumor, especially in the case of Castleman’s disease.
Intravenous immunoglobulin (IVIg) should be administered
before, during, and after the operation.14 Immunosuppression
is an important component of treatment of PNP, and high-dose
corticosteroids are first line. 17 Cyclosporine, azathioprine 11,
mycophenolate mofetil,18 and other steroid-sparing agents may
be used as adjunct therapy. If these agents fail to control the
disease, alternative agents such as plasmapheresis, IVIg14, and
rituximab19,20 have been used with mixed results. Unfortunately,
response to treatment is generally poor, and PNP frequently
results in premature death compared to the average life
expectancy associated with the underlying malignancy.3,15 The
prognosis is generally more favorable in patients with benign
neoplasms, such as Castleman’s syndrome or thymoma3.
In summary, paraneoplastic pemphigus is a rare, polymorphous
blistering disease with a predilection for the mucosal surfaces
in the setting of an associated neoplasm. The disease should
be suspected if histology demonstrates acantholysis and
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dyskeratotic kerotinocytes, and if characteristic immunofluorescence is noted. Prompt diagnosis and treatment, along with
search for underlying neoplasm, is appropriate as progression of
the disease can result in death.
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